全文获取类型
收费全文 | 7016篇 |
免费 | 505篇 |
国内免费 | 57篇 |
专业分类
耳鼻咽喉 | 81篇 |
儿科学 | 189篇 |
妇产科学 | 106篇 |
基础医学 | 997篇 |
口腔科学 | 187篇 |
临床医学 | 714篇 |
内科学 | 1632篇 |
皮肤病学 | 99篇 |
神经病学 | 652篇 |
特种医学 | 373篇 |
外科学 | 1047篇 |
综合类 | 72篇 |
一般理论 | 5篇 |
预防医学 | 377篇 |
眼科学 | 130篇 |
药学 | 366篇 |
中国医学 | 8篇 |
肿瘤学 | 543篇 |
出版年
2023年 | 51篇 |
2022年 | 42篇 |
2021年 | 150篇 |
2020年 | 135篇 |
2019年 | 170篇 |
2018年 | 206篇 |
2017年 | 152篇 |
2016年 | 169篇 |
2015年 | 208篇 |
2014年 | 286篇 |
2013年 | 356篇 |
2012年 | 538篇 |
2011年 | 513篇 |
2010年 | 348篇 |
2009年 | 291篇 |
2008年 | 477篇 |
2007年 | 469篇 |
2006年 | 403篇 |
2005年 | 389篇 |
2004年 | 322篇 |
2003年 | 313篇 |
2002年 | 277篇 |
2001年 | 61篇 |
2000年 | 45篇 |
1999年 | 71篇 |
1998年 | 75篇 |
1997年 | 67篇 |
1996年 | 73篇 |
1995年 | 69篇 |
1994年 | 63篇 |
1993年 | 62篇 |
1992年 | 39篇 |
1991年 | 37篇 |
1990年 | 36篇 |
1989年 | 52篇 |
1988年 | 63篇 |
1987年 | 46篇 |
1986年 | 39篇 |
1985年 | 32篇 |
1984年 | 36篇 |
1983年 | 33篇 |
1982年 | 40篇 |
1981年 | 38篇 |
1980年 | 25篇 |
1979年 | 21篇 |
1978年 | 20篇 |
1976年 | 15篇 |
1975年 | 19篇 |
1974年 | 18篇 |
1972年 | 13篇 |
排序方式: 共有7578条查询结果,搜索用时 15 毫秒
1.
Hope S. Rugo Jens Huober Jos A. GarcíaSenz Norikazu Masuda Joo Hyuk Sohn Valerie A.M. Andre Susana Barriga Joanne Cox Matthew Goetz 《The oncologist》2021,26(1):e53-e65
BackgroundAbemaciclib demonstrated efficacy in hormone receptor‐positive, human epidermal growth factor receptor 2‐negative advanced breast cancer. Here we provide a comprehensive summary of the most common adverse events (AEs), their management, and whether AEs or dose reductions influenced progression‐free survival (PFS), in the MONARCH 2 and 3 trials.Materials and MethodsIncidence of the most clinically relevant AEs, management, and outcomes were summarized. Time‐dependent covariate analyses examined the impact of dose reductions on PFS. PFS was estimated for patients with and without early onset of diarrhea or neutropenia.ResultsThe most frequently reported AE was diarrhea, with clinically significant diarrhea (grade ≥2) reported for 42.8% of patients taking abemaciclib. Median time to onset was 1 week, and duration ranged from 6 to 12 days, depending on grade and study. Diarrhea was adequately managed by antidiarrheal medication (72.8%), dose omissions (17.3%), and reductions (16.7%). The highest rates of grade ≥2 diarrhea were observed in the first cycles and decreased in subsequent cycles. Neutropenia (grade ≥3) occurred in 25.4% of abemaciclib‐treated patients. Neutropenia resolved with dose omissions (16.8%) and/or dose reductions (11.2%). Incidence of febrile neutropenia (0.7%) or other relevant grade ≥3 hematological events (<9%) was low. Venous thromboembolic events (5.3%) were primarily treated with anticoagulants. Interstitial lung disease/pneumonitis (3.4%) was treated with corticosteroids and/or antibiotics. PFS benefit of abemaciclib was not impacted by dose reductions or early onset of toxicities.ConclusionAbemaciclib was generally well tolerated. The most common AEs were effectively managed by supportive medications, and/or dose adjustments, with no detriment to PFS.Implications for PracticeTreatment with abemaciclib plus fulvestrant or nonsteroidal aromatase inhibitors is generally well tolerated in patients with hormone receptor‐positive, human epidermal growth factor receptor 2‐negative advanced breast cancer. In MONARCH 2 and MONARCH 3, any‐grade diarrhea and grade ≥3 neutropenia were effectively managed with supportive medication and/or dose adjustment. Venous thromboembolic events were treated with anticoagulants and did not often require treatment discontinuation. Interstitial lung disease/pneumonitis was infrequent and treated with corticosteroids and/or antibiotics. Clinicians should be aware of and implement management strategies, including dose adjustments according to local labels, for commonly occurring and serious adverse events to ensure continued treatment and optimize clinical benefit/risk ratio. 相似文献
2.
Andre Briosa e Gala MD Michael T. B. Pope BM James D. Newton MD Sam Dawkins MD PhD Timothy R. Betts MD 《Journal of cardiovascular electrophysiology》2021,32(6):1655-1657
Percutaneous mechanical closure of the left atrial appendage (LAA) is a valuable stroke prevention strategy in patients with atrial fibrillation and contraindication to oral anticoagulation. LAA thrombus is a common finding in patients with atrial fibrillation and frequently fails to resolve despite therapeutic anticoagulation. In this scenario, LAA occlusion device implant is generally discouraged due to the high risk of thrombus dislodgement and embolization; however, alternative management options are limited. We report the first case of a successful LAA occlusion device (Watchman-FLX) implant in the presence of a proximal thrombus. 相似文献
3.
Annekathrin Haberland Oxana Krylova Heike Nikolenko Peter Gttel Andre Dallmann Johannes Müller Hardy Weisshoff 《Viruses》2021,13(5)
COVID-19 is a pandemic respiratory disease that is caused by the highly infectious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Anti-SARS-CoV-2 antibodies are essential weapons that a patient with COVID-19 has to combat the disease. When now repurposing a drug, namely an aptamer that interacts with SARS-CoV-2 proteins for COVID-19 treatment (BC 007), which is, however, a neutralizer of pathogenic autoantibodies in its original indication, the possibility of also binding and neutralizing anti-SARS-CoV-2 antibodies must be considered. Here, the highly specific virus-neutralizing antibodies have to be distinguished from the ones that also show cross-reactivity to tissues. The last-mentioned could be the origin of the widely reported SARS-CoV-2-induced autoimmunity, which should also become a target of therapy. We, therefore, used enzyme-linked immunosorbent assay (ELISA) technology to assess the binding of well-characterized publicly accessible anti-SARS-CoV-2 antibodies (CV07-209 and CV07-270) with BC 007. Nuclear magnetic resonance spectroscopy, isothermal calorimetric titration, and circular dichroism spectroscopy were additionally used to test the binding of BC 007 to DNA-binding sequence segments of these antibodies. BC 007 did not bind to the highly specific neutralizing anti-SARS-CoV-2 antibody but did bind to the less specific one. This, however, was a lot less compared to an autoantibody of its original indication (14.2%, range 11.0–21.5%). It was also interesting to see that the less-specific anti-SARS-CoV-2 antibody also showed a high background signal in the ELISA (binding on NeutrAvidin-coated or activated but noncoated plastic plate). These initial experiments suggest that the risk of binding and neutralizing highly specific anti-SARS CoV-2 antibodies by BC 007 should be low. 相似文献
4.
Suen Paulo J. C. Doll Sarah Batistuzzo Marcelo C. Busatto Geraldo Razza Lais B. Padberg Frank Mezger Eva Bulubas Lucia Keeser Daniel Deng Zhi-De Brunoni Andre R. 《European archives of psychiatry and clinical neuroscience》2021,271(1):101-110
European Archives of Psychiatry and Clinical Neuroscience - Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation intervention investigated for the treatment of... 相似文献
5.
6.
de Morais Pollyana C. V. Gama Allyne F. Fernandes Gabrielle M. Oliveira Andre H. B. Lima Marcielly F. B. dos Santos Felipe R. Martins Davi A. Nascimento Ronaldo F. Cavalcante Rivelino M. 《Bulletin of environmental contamination and toxicology》2019,102(1):66-76
Bulletin of Environmental Contamination and Toxicology - This work describes the development of an analytical protocol combining cleanup by liquid–solid extraction and GC–MS for the... 相似文献
7.
8.
9.